Fate Therapeutics announced plans to start a Phase 2 clinical trial for FT819, a CAR T-cell therapy targeting lupus nephritis, in the second half of 2026. The therapy has received FDA support through the CDRP program and RMAT designation, highlighting its potential for accelerated approval. Clinical data show FT819 is effective and safe, with ongoing trials expanding patient enrollment and exploring less intensive treatment regimens. The company also reported a strong financial position with $174.8 million in cash, extending its operating runway into 2028, supporting continued development of FT819 and next-generation CAR T-cell therapies.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
CHARBONE Corporation has increased its helium delivery fleet from one to five units to meet rising demand caused by global helium supply disruptions, notably from Qatar. This expansion supports North American customers in sectors like semiconductors ...
Citi has started coverage of Hikma Pharmaceuticals with a 'buy' rating and a £17 price target, highlighting the company's strategic shift towards differentiated products and US manufacturing investments. The broker sees a 14% potential share price re...
Xenon Pharmaceuticals is evolving into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform. Its lead drug candidate, azetukalner, has shown strong effectiveness in treating refractory focal onset seizures and ...
